Here, we examined the consequences of prolonged PD-L1 inhibition in vivo on tumor cells and identified a unique secretory signature that was associated with acquired resistance, enriched for numerous ISGs, and tightly regulated by type I IFN signaling. The gene discussed is CD274; the disease is neoplasm.